An interventional study of MiniMed® Pro-set® and MiniMed® Quick-set® in Diabetes Mellitus, Type 1, sponsored by Becton, Dickinson and Company. Withdrawn. Open to participants aged 13 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-09-14.
Sponsored by Becton, Dickinson and Company · Not applicable, Interventional, and Other
Open label, randomized 2-period cross-over study comparing two continuous subcutaneous insulin infusion sets ; MiniMed® Pro-set® with BD FlowSmart™ technology and MiniMed® Quick-set®
3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →Becton, Dickinson and Company is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Must be using one of the following Medtronic insulin pumps with the Paradigm connector (note 670G excluded) for at least 6 months prior to enrollment. These pumps must have the ability to upload data to Medtronic CareLink Therapy Management software.
Exclusion Criteria:
Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
Device: MiniMed® Pro-set® · Device: MiniMed® Quick-set®
Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia
Time frame: 6 hours from time of insertion
Compare Pro-set® vs. Quick-set® for set removals due to hyperglycemia; > 400mg/dl.
Time frame: 6 hours from time of insertion
Compare Pro-set® vs. Quick- set® for set removals due to set failure; hyperglycemia >250mg/dl.
Time frame: 72 hours of set wear that occurs at 6 hours or later after insertion
Compare Pro-set® vs. Quick- set® for set removals at less than 60 hours post insertion.
Time frame: 60 hours post insertion
Compare Pro-set® vs. Quick- set® for duration of wear
Time frame: % reaching 12 hours, % reaching 24 hours, % reaching 36 hours, % reaching 48 hours, % reaching 60 hours, and % reaching 72 hours)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Becton, Dickinson and Company